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Increasing evidence indicates that accumulation of misfolded proteins in the form of oligomers,
protoﬁbrils or amyloid ﬁbrils, and their consequences in triggering intracellular signaling cascades
with toxic consequences represent unifying events inmany of slowly progressive neurodegenerative
disorders. Studies with small compounds or molecules, known to recognize and disrupt amyloido-
genic structures, have proven efﬁcient in promoting clearance of protein aggregates in experimental
models of systemic and localized forms of amyloidoses. Doxycycline and EGCG were efﬁcient in
removing aggregates in pre-clinical studies in a transgenic mouse model for transthyretin (TTR) sys-
temic amyloidosis and represent an opportunity to address mechanisms and key players in deposit
removal. Extracellular chaperones, such as clusterin and metalloproteinases play an important role
in this process.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Extracellular protein misfolding and aggregation occurring in
systemic amyloidosis triggers inﬂammation, oxidative stress, ma-
trix remodeling, the unfolded-protein-response and ER pathways
that resemble in many aspects, including common molecular play-
ers and scenarios, to those described in local amyloidoses affecting
for example the central nervous system (CNS), such as Alzheimer
Disease. Thus, similarities and dissimilarities in toxicity found be-
tween the CNS and the periphery are very useful to pinpoint and
guide us to the treatment of aging-associated neurodegenerative
disorders. Understanding the two-way crosstalk between the
extracellular milieu and the cell is a major trend in diseases related
to protein aggregation. In particular, mechanisms involved in the
clearance of protein aggregates, both extra and intracellular, are
pivotal and need detailed analyses for the development of thera-
peutic strategies. Studies with small compounds or molecules,
such as antibodies [1,2] known to recognize and disrupt amyloido-
genic structures, have proven efﬁcient in removing and promoting
clearance of protein aggregates in studies with experimental mod-
els of misfolding disorders. However, the mechanisms and keyrobiology, IBMC, R. Campo
57.
eida), mjsaraiv@ibmc.up.pt
al Societies. Published by Elsevierplayers in these processes are largely unknown. Extracellular
molecular chaperones are capable to repair or target damaged pro-
teins to degradation by binding to extracellular misfolded proteins
and by promoting their disposal either by endocytosis for intracel-
lular degradation or degradation by the extracellular matrix.
Herein, we give examples of studies designed to approach the is-
sue of clearance of extracellular deposition of transthyretin (TTR), a
key protein associated with familial amyloidotic polyneuropathy
(FAP). FAP is a fatal neurodegenerative disorder characterised by
the extracellular deposition of aggregates and ﬁbrils of mutant
forms of TTR, particularly in nerves and ganglia of the peripheral
nervous system (PNS). The most common TTR mutation is a substi-
tution of Valine for Methionine at position 30 (V30M TTR) that pre-
disposes TTR to form aggregates and ﬁbrils. FAP initially presents
with symptoms that are associated with sensory and autonomic
nervous system (ANS) dysfunction. These include loss of pain and
temperature sensation in the distal limbs, impotence, gastrointesti-
nal disturbances, bladder dysfunction and postural hypotension. As
FAP progresses, sensory deﬁciencies extend to more proximal re-
gions of limbs and cardiac insufﬁciency and mal-absorption from
the gut become common. In addition, motor involvement results
in a progressive loss of reﬂexes and muscle wasting in later stages
of FAP [3]. Over 600 kindreds have been identiﬁed in Portugal
which constitutes the largest world focus of the disease.
TTR is a transport protein for thyroid hormones (namely, thy-
roxine – T4) and vitamin A (through a complex with retinol bindingB.V. Open access under CC BY-NC-ND license.
2892 M.R. Almeida, M.J. Saraiva / FEBS Letters 586 (2012) 2891–2896protein – RBP) and is predominantly synthesized in the liver. Be-
cause most circulating mutant TTR is synthesized in the liver, liver
transplant has been used to treat FAP since 1990. However, univer-
sal and less invasive therapeutics are mandatory. Proposed phar-
maco-therapeutic strategies for FAP are similar to the approaches
taken for other systemic amyloidoses, such as lowering the levels
or stabilizing the native structure of the plasma protein precursor,
inhibiting aggregation, disrupting TTR amyloid by selective mole-
cules, and counteracting cellular toxicity.
Based on the knowledge gathered from the various in vitro and
in vivo approaches to elucidate TTR aggregation and toxicity, dif-
ferent multicenter clinical trials are underway including RNAi
silencing methodology to lower liver TTR expression – ALN-
TTR01 – (www.Alnylam.com); in a transgenic mice model for the
human TTR V30M (described below), this compound showed dura-
ble suppression, as much as 90%, for both TTR mRNA and protein
levels in plasma and reduction of deposition in extra-hepatic tis-
sues [4]. Phase I/II human clinical studies are underway to evaluate
the safety and tolerability of this drug in V30M FAP patients.
Stabilization of the native structure of plasma TTR is achieved by
Tafamidis (now proprietary of Pﬁzer) as explained below; results
from an 18-month phase II/III randomized double-blind trial
showed improvement of body mass index and slight stabilization
in nerve function [5]. As referred to previously, once the clinical
symptoms are triggered in FAP, disease evolution takes several
years; thus, the initial studies have been extended to assess the
usefulness of this drug in FAP treatment and also to investigate
the mechanisms underlying the results found in non-responders.
It is clear that more than a single approach to treat FAP effec-
tively is mandatory; in this regard, the experience achieved so
far with clearance based approaches is very promising and next
described.
2. Modulation of the heat-shock response: extracellular
chaperones
The heat-shock response was investigated in FAP. Up-regulation
of Hsp27 and Hsp70 expression related to the presence of extracel-
lular TTR aggregates was documented in human FAP biopsies as
compared to normal controls. TTR aggregates did not co-localize
with Hsps suggesting that extracellular TTR tissue deposits are able
to induce an intracellular stress response. Moreover, the heat-
shock transcription factor-1 (HSF-1) was up-regulated and local-
ized to the nucleus [6].
It was hypothesized that HSF-1 could be involved in FAP path-
ogenesis as a cell-defense mechanism against the presence of
extracellular TTR deposits and that disruption of the heat-shock re-
sponse would aggravate TTR deposition. A mouse model express-
ing the human TTR-V30M in an HSF-1-null background was
characterized. The lack of HSF-1 expression lead to extensive and
earlier non-ﬁbrillar TTR deposition, particularly in the gastrointes-
tinal tract, evolving into ﬁbrillar material in distinct organs, includ-
ing the peripheral and autonomic nervous systems; in contrast,
V30M animals in the wild-type background do not display deposi-
tion in the PNS and ANS. As in the human disease, liver, brain, and
spinal cord did not present deposition in this animal model. Fur-
thermore, inﬂammatory stress and a reduction in unmyelinated
nerve ﬁbers were observed, as in human patients, indicating that
HSF-1-regulated genes are involved in FAP, modulating TTR tissue
deposition [7].
Clusterin, also known as apolipoprotein J, is an ubiquitous
highly conserved secreted protein. Clusterin inhibits protein aggre-
gation in an ATP independent manner after binding to misfolded
proteins forming soluble, high molecular weight complexes [8,9].
It was shown that clusterin, much like small heat shock proteins,does not have the capability to refold non-native enzymes by itself;
however clusterin is able to keep non-native proteins in a stabi-
lized state until Hsp70 can refold them. Clusterin is present in most
physiologic ﬂuids and described to act as a molecular chaperone in
the extracellular milieu [10]. Several functions have been recog-
nized for clusterin other than being a molecular chaperone; this
protein has a role in: (i) control of cell–cell and cell–matrix inter-
actions; (ii) apoptosis regulation; (iii) lipid transport and comple-
ment regulation. Clusterin gene expression is induced by a
variety of factors including stress, cellular growth, differentiation
and ageing. HSF-1 is also responsible for clusterin expression
induction [11]. In vitro data reported that clusterin is able to inhi-
bit ﬁbril formation of several different proteins, including b-amy-
loid and a-synuclein [12,13]. Clusterin binds b-amyloid and
forms a complex that is internalized for degradation by megalin
(low-density lipoprotein receptor related protein 2 – LRP2); uptake
of these complexes lowers amyloid toxicity [14]. Facilitated clear-
ance of extracellular misfolded proteins by clusterin was also doc-
umented in vivo [15]. Thus, the available data support the notion
that besides a role as a molecular chaperone, stabilizing proteins
and inhibiting their aggregation, clusterin also has an important
role in the clearance of extracellular aggregates through megalin
mediated endocytosis. In the case of FAP, we have shown clusterin
overexpression in tissues with TTR deposition of V30M transgenic
mice with a full HSF-1 response; by double immunohistochemis-
try, clusterin co-localizes with both ﬁbrillar and non-ﬁbrillar TTR
deposits in human nerve and is identiﬁed in TTR ﬁbrils extracted
from human kidney. In vitro studies revealed that incubation of
SH-SY5Y neuroblastoma cells with TTR oligomers leads to intracel-
lular clusterin over-expression. Moreover, clusterin secretion was
also signiﬁcantly increased in the medium of cells incubated with
TTR oligomers and association of clusterin with TTR aggregates ob-
served. Furthermore, clusterin modulates TTR aggregation, as clus-
terin deprivation in cellular models stimulates extracellular TTR
aggregation [16].
Further details of clusterin chaperone activity, scavenger prop-
erties and mechanisms of other extracellular chaperones acting in
FAP are warranted.
3. Pharmacological agents
3.1. Clearance by disaggregation of TTR amyloid ﬁbrils: doxycycline
Some years ago it was reported that 40-iodo-40-doxy doxorubi-
cin inhibits amyloid formation and promotes the reabsorption of
amyloid deposits [17]. Subsequently, tetracycline antibiotics were
screened for these properties based on their structural homologies
with the aglycone moiety of the anthracyclines. The ﬁrst demon-
stration was by in vitro studies with the human prion protein
(PrP) whereby tetracyclines were shown to bind to human PrP,
to hinder assembly into amyloid ﬁbrils, and to prevent neuronal
death and astrocyte proliferation induced by PrP peptides
‘‘in vitro’’ [18]. It was found that doxycycline was particularly po-
tent in disrupting TTR-like amyloid and that the generated assem-
blies did not display cytotoxic properties in caspase-3 activation
assays [19]. In vivo studies corroborated the in vitro ﬁndings; when
doxycycline was administrated to 23–28 month old V30M TTR
transgenic animals in the drinking water over a period of 3 months,
immunohistochemistry revealed that Congo red positive material
was only observed in the control, non-treated group. Moreover,
immunohistochemistry for several markers associated with TTR
amyloid deposition such as matrix metalloprotease 9 (MMP-9)
[20] and serum amyloid P component (SAP) was performed. Signif-
icantly lower levels of MMP-9 were found in the treated animals
when compared with the control group and mouse SAP was absent
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with congophilic deposits. These results indicated that doxycycline
is capable of disrupting Congo red positive TTR amyloid deposits
and decreases standard markers associated with ﬁbrillar deposi-
tion, being suggested as a potential drug in the treatment of amy-
loidosis [21]. Doxycycline can also disassemble preformed b2
microglobulin amyloid ﬁbrils and at the same inhibits their forma-
tion [22].
More recently, in vitro studies demonstrated that doxycycline
directly disrupted the formation of recombinant light chains (LC)
amyloid ﬁbrils. Furthermore, treatment of ex vivo LC amyloid ﬁ-
brils with doxycycline reduced the number of intact ﬁbrils and
led to the formation of large disordered aggregates; in vivo studies
in a CMV-k6 transgenic model for AL amyloidosis showed clear-
ance of amyloid deposits in the stomach after doxycycline treat-
ment [23].
All together these evidences led to the approval by the Euro-
pean Medicines Agency of the application of doxycycline as an or-
phan drug in the treatment of FAP (EU/3/12/955) and b2
microglobulin systemic amyloidosis (EU/3/12/961). Detailed anal-
yses on the mechanism of action of doxycycline on amyloid ﬁbrils
await elucidation.
3.2. Clearance by modulation of the TTR aggregation pathway: EGCG
It is widely accepted that the mechanism of TTR amyloid forma-
tion involves destabilization of the TTR tetramer, due to environ-
mental or genetic conditions, namely mutations, leading to
dissociation in monomers with an altered conformation that are
more prone to aggregation and ﬁbril formation [24]. Considering
this mechanism, one of the most explored approaches in TTR amy-
loidosis was the search for compounds that speciﬁcally bind to
TTR, in particular at T4 binding sites, stabilizing the tetramer and
blocking the cascade of aggregation and ﬁbril formation. Thus a
wide variety of small compounds presenting structural similarities
with thyroxine, the natural TTR ligand, have been proposed and
tested as TTR amyloid inhibitors [25,26]. Those compounds are
very speciﬁc in their binding at the TTR–T4 binding sites establish-
ing interactions with different TTR monomers and promoting TTR
stabilization; such is the case of Tafamidis, above referred.
Recently, several compounds have been referred to act as non-
speciﬁc aggregation inhibitors of different proteins involved in
misfolding diseases as is the case of Ab and a-synuclein [27]. The
non-speciﬁc inhibitors hinder formation of oligomeric and/or pre-
ﬁbrillar species, probably recognizing common structural or con-
formational properties and through a still unknown mechanism
of action may also disrupt pre-existing amyloid ﬁbrils [28]. This
concept of general modulators of the aggregation pathway is gain-
ing increasing relevance. Among those modulators, particular
interest has been raised by natural polyphenols such as epigalloca-
techin gallate (EGCG), from green tea, and curcumin [29]. Based on
this concept of general modulators of amyloid formation, EGCG
and curcumin have also been tested in TTR-related amyloidosis.
Studies in vitro and in a cell culture system using different amyloi-
dogenic TTR variants demonstrated that EGCG and curcumin bind
to TTR, increase its tetrameric conformational stability, modulate
the intermediary species formed and inhibit TTR aggregation
[30,31] (Fig. 1a). However, contrary to other polyphenols, EGCG
does not bind at the T4 binding channel on TTR [30]. Crystal struc-
ture of the TTR-EGCG complex demonstrated that there are 3 dif-
ferent binding sites for EGCG on TTR [32]. One of these sites is
located in a region of the TTR tetramer that allows contact of EGCG
with both TTR dimers, indicating that the interaction of EGCG with
TTR at this binding site contributes to the TTR tetramer stabiliza-
tion. This site seems to be the preferential binding site for EGCG.
The other two binding sites are located at the surface of differentmonomers in the TTR molecule and might be involved in the olig-
omerization of TTR tetramers, leading to the formation of non-
toxic, off-pathway aggregates [30,32].
EGCG was also demonstrated to act as amyloid ﬁbril disruptor
in vitro as assayed by transmission electron microscopy (TEM)
and dynamic light scattering (DLS) (Fig. 1b) [33]. These results
were further conﬁrmed by in vivo studies using two FAP mice
models, the transgenic mice expressing the human TTR V30M
and the transgenic TTR V30M in a HSF-1 null background, at differ-
ent stages of TTR deposition. The results obtained revealed that
EGCG inhibited TTR deposition when treated in a precocious stage,
when TTR starts to deposit (at 3–4 months of age) in the gastroin-
testinal tract and in the PNS. Inhibition of TTR deposition, evalu-
ated by immunohistochemistry and immunoblotting of mice
tissues after EGCG treatment for 6 weeks, was accompanied by a
decrease of the biomarkers associated with the disease such as
ER-stress markers BiP and P-eIF2a, Fas and 3-nitrotyrosine
(Fig. 1c) [34]. Furthermore, as pointed out by several authors, EGCG
inhibitory effect on the amyloid formation cascade is not limited to
early intermediates of ﬁbrillogenesis, since EGCG is also able to
efﬁciently remodel mature ﬁbrils made from a variety of amyloido-
genic proteins into smaller, non-toxic unstructured protein aggre-
gates [30,34]. Therefore, when similar in vivo studies were
performed with aged TTR V30M mice that simultaneously present
non-ﬁbrillar and ﬁbrillar TTR forms deposited in tissues, EGCG was
also found to disaggregate amyloid deposits. This was particularly
evident by Congo red birefringence analysis of stomach sections
(Fig. 1d). These results were further supported by substantial de-
crease of remodeling extracellular matrix markers, MMP-9 and
SAP, in EGCG treated mice, which was concomitant with amyloid
clearance and indicative of inﬂammation reduction and matrix
recovery.
Preliminary results from similar studies in vivo with curcumin
indicate that it also acts as an effective TTR aggregation modulator
[33].
Very recently, based on the above referred in vitro and animal
studies with EGCG and also on studies on patients with AL amyloi-
dosis [35,36] a preliminary study was conducted on a cohort of TTR
amyloidosis patients, including systemic senile amyloidosis (SSA),
where normal TTR deposits in the heart of old people, and variant
TTR amyloidosis [37]. After one year of treatment with green tea or
green tea extract, 86% of the treated patients presented a decrease
of cardiac wall thickness and mass as revealed mainly by cardiac
magnetic resonance imaging (CMRI) indicating that green tea,
mainly EGCG, halted TTR deposition and increased TTR amyloid
deposits clearance. Though a randomized placebo-controlled study
is necessary, as proposed by the authors of the study [37], the re-
sults point to a positive therapeutic effect of EGCG on TTR amyloi-
dosis, in particular in cardiac forms. Moreover, it must be stressed
that EGCG possesses radical scavenging properties and it is rele-
vant as an antioxidant agent [38]. Thus we should consider that
these characteristics might potentiate its neuroprotective action
as an anti-amyloid compound.
Besides these natural modulators, synthetic compounds have
been designed to interact with general particular small sequences
of amino acids in aggregated proteins and not with speciﬁc pro-
teins [28]. Those synthetic compounds designated by ‘‘molecular
tweezers’’ interfere with different kinds of interactions in aggre-
gated proteins namely electrostatic, hydrogen or van der Walls
interactions, and modulate the aggregation pathway, remodel the
intermediary species formed and also disrupt pre-existent amyloid
ﬁbrils. Some molecular tweezers have already been tested in vivo
in mice models for a-synuclein and Ab aggregation [39] and consti-
tute also great candidates for TTR amyloidosis.
Detailed knowledge of the mechanism of action of all these
modulators of aggregation will contribute to disclose unknown
Fig. 1. EGCG inhibits TTR aggregation and disrupts TTR ﬁbrils. (a) DLS (dynamic light scattering) analysis of TTR (TTR Y78F, amyloidogenic variant) in the presence of EGCG
(red line) and in its absence (control) (black line). EGCG inhibits TTR aggregation as evident by the very small percentage of TTR aggregates and by the increase of the
percentage of soluble TTR, as compared to control. (b) DLS analysis of pre-formed aggregates and ﬁbrils of the amyloidogenic TTR variant TTR L55P (t = 0) and after incubation
for 4 days with EGCG. Aggregates and ﬁbrils were disrupted and converted to a polydisperse size particle population (bottom graph). (c) Immunohistochemistry analysis of
tissues from mice treated with EGCG and controls. Top panels: transgenic mice TTR V30M treated with EGCG present a decrease of approximately 50% of non-ﬁbrillar TTR
deposition in the gastro-intestinal tract as compared to non-treated mice (control). Bottom panels, transgenic TTR V30M mice in HSF-1 deﬁcient background treated with
EGCG present a decrease of TTR deposition of approximately 66% in dorsal root ganglia (DRG). (d) Analysis of tissues from old (17 months of age) TTR V30M transgenic mice
treated with EGCG and controls. Top panels: immunohistochemistry analysis shows an evident clearance of the TTR deposited in tissues (reduction of approximately 42% in
TTR deposition) as compared to non-treated mice. Bottom panels: Congo red staining of stomach. Congo red positive deposits were decreased in about 40% of mice treated
with EGCG.
Fig. 2. Combination therapies in the treatment of TTR amyloidosis. Lowering the
levels or stabilizing the native structure of TTR, inhibiting aggregation, disrupting
TTR amyloid, and counteracting cellular toxicity are potential therapies for TTR
amyloidosis. Combination therapies by administration of selected compounds that
act synergistically, such as doxycycline and TUDCA should be emphasized, as well
as compounds with different modes of action such as EGCG.
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intermediates in amyloid formation and to design more potent and
efﬁcient therapeutic agents for TTR amyloidosis.
4. Combination therapies
Another drug, which was tested in TTR transgenic animals and
was effective to counteract TTR aggregation, was tauroursodeoxy-
cholic acid (TUDCA). TUDCA is a unique natural compound that
acts as a potent anti-apoptotic and anti-oxidant agent, reducing
cytotoxicity in several neurodegenerative diseases [40]. Since oxi-
dative stress, apoptosis, and inﬂammation are associated with TTR
deposition in FAP [41], the possible therapeutic application of TUD-
CA in this disease was investigated. It was shown by semi-quanti-
tative immunohistochemistry and western blotting that
administration of TUDCA to a transgenic mouse model of FAP de-
creased apoptotic and oxidative biomarkers namely the ER chaper-
one BiP, the Fas death receptor, and oxidation products such as 3-
nitrotyrosine. Most importantly, TUDCA treatment signiﬁcantly re-
duced TTR toxic aggregates as much as 75% [42].
We recently showed that combined cyclic drug administration
of doxycycline and TUDCA, resulted in signiﬁcant reduction in
TTR deposition and associated tissue markers in the TTR V30M
transgenic mouse model [43]. The observed synergistic effect of
doxycycline/TUDCA within the range of human-tolerable quanti-
ties prompted their application in FAP, particularly in the earlystages of disease. For this purpose, a phase-II clinical study for
TTR amyloidosis is underway in Italy (www.clinicaltrials.gov –
transthyretin amyloidosis) with preliminary very promising re-
sults. Thus, the neuropathy impairment score in 20 enrolled pa-
tients in the lower limbs remained stable during the time of the
trial (1 year) and no clinical progression of cardiac involvement
M.R. Almeida, M.J. Saraiva / FEBS Letters 586 (2012) 2891–2896 2895was observed [44]. These studies are currently extended to differ-
ent TTR amyloidosis populations.
As summarized in Fig. 2, one of the main messages of this par-
ticular study is that combination therapies, such as the combina-
tion of doxycycline and TUDCA should be applied in the
treatment of TTR systemic amyloidosis. In this regard, pre-clinical
studies in animal models are pivotal not only in the assessment of
potential synergistic effects between individual drugs presenting
diverse modes of action as well as single drugs with different
modes of action, such as EGCG.
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